

Artikelnummer hänvisar till Läkemedelsbranschens Etiska Regelverk (LER) [Kap. 2, avd. 3]

Rapport värdeöverföringar Tillotts Pharma AB Sverige 2025

Datum för publicering: 2025-05-26

Fulständigt namn (artikel 2)	HCP: Ort där verksamheten huvudsakligen bedrivs HCO: ort där verksamheten bedrivs (registrerad adress) (artikel 9)	Land där verksamheten huvudsakligen bedrivs (artikel 1)	Adress där verksamheten huvudsakligen bedrivs t ex klinik/mottagning/vårdenhet/avdelning (artikel 9)	Unik identifierare - FRIVILLIG UPPGIFT (artikel 9)	Donationer till HCOs (artikel 9)	Bidrag till kostnader för arrangemang (artikel 9)				Kostnader för uppdrag och konsultation (artikel 9)		TOTALT (SEK)	FRIVILLIG UPPGIFT
						Sponsoravtal med HCO / tredje part utsedd av HCO att genomföra ett arrangemang	Registreringsavgifter	Resor och logi	Arvode	Utlägg för omkostnader förknippade med uppdraget eller konsultationen t ex resor och logi			
RAPPORT PER PERSON - en rad per HCP som anger summan av alla värdeöverföringar under ett kalenderår till en enskild HCP. Detaljer bör endast vara tillgängliga för mottagaren eller för samråd med myndigheter, där så är lämpligt													
Marie Andersson	Borås	Sverige	Södra Älvsborgs sjukhus 501 82 Borås 231000-0131		E/T	E/T	E/T	E/T	15000			15000	
Daniel Bergemalm	Örebro	Sverige	Örebro Universitetssjukhus Mag-Tarm och leversektionen 701 85 Örebro		E/T	E/T	E/T	E/T	20000			20000	
Eva Blackås	Göteborg	Sverige	Sahlgrenska Universitetssjukhuset Magtarmmottagnigen, 413 46 Göteborg		E/T	E/T	E/T	E/T	3900			3900	
Karolina Exlov	Stockholm	Sverige	Södersjukhuset Sjukhusbacken10 118 83 Stockholm		E/T	E/T	E/T	E/T	10000			10000	
Carl-Johan Fränkel	Lund	Sverige	Själens Universitetssjukhus Lund Hellsogatan 3 221 85 Lund		E/T	E/T	E/T	E/T	15770			15770	
Kristin Wenmo Zuk	Stockholm	Sverige	Södersjukhuset Sjukhusbacken10 118 83 Stockholm		E/T	E/T	E/T	E/T	5000			5000	
Hans Strid	Solna	Sverige	Karolinska Universitetssjukhuset Eugeniavägen 3 171 86 Solna		E/T	E/T	E/T	E/T	5000			5000	
DVRIGT, ej rapporterat ovan - där information inte kan lämnas ut per individ med hänsyn till Dataskyddsförordningen						E/T	E/T	E/T	E/T	31 500	1439	32939	
Totalt belopp hänförligt till värdeöverföringar till dessa mottagare - artikel 10						E/T	E/T	E/T	E/T	3	7		
% av totala antalet mottagare enskilda HCPs - artikel 10						E/T	E/T	E/T	E/T	30 %	10%		
RAPPORT PER HCO - en rad per HCO (dvs. alla värdeöverföringar under ett kalenderår för en HCO ska summeras; specificering bör endast vid behov vara tillgänglig för den enskilda mottagaren eller för samråd med myndigheter)													
Ersta Diakonalsällskap	Stockholm	Sverige	Ersta Diakonalsällskap Fjällgatan 44 116 28 Stockholm			55000	E/T	E/T				55000	
Capio Gastro Center Stockholm AB	Stockholm	Sverige	Valhallavägen 91, 114 86 Stockholm				E/T	E/T	8000			8000	
Ersta Sjukhus	Stockholm	Sverige	Folkungagatan 125 116 30 Stockholm				E/T	E/T	30000			30000	
Lindforce AB	Stockholm	Sverige	Folkungagatan 71 116 22 Stockholm				E/T	E/T	20000			20000	
Insamlingsstifelsen Mag-Tarmfonden	Stockholm	Sverige	Artillerigatan 6 114 51 Stockholm	50000			E/T	E/T				50000	
MakilanMaden Gastrokonsult AB	Malmö	Sverige	Albinergatan 5A, 214 67 Malmö				E/T	E/T	18000	1211		19211	
SFGO, Svensk förening för gastroenterologisk omvårdnad	Ljungsbro	Sverige	Kröningsgatan 8, 585 73 Ljungsbro	20000			E/T	E/T				20000	
SOIB, the Swedish Organisation for the Study of Inflammatory Bowel Diseases	Göteborg	Sverige	Sahlgrenska Universitetssjukhuset, östra kirurgkliniken, 416 85			40000	E/T	E/T				40000	
Svensk Intermedicinsk Förening	Kalmar	Sverige	Länssjukhuset Kalmar 392 44 Kalmar			60000	E/T	E/T				60000	
Svensk Geriatrisk Förening	Stockholm	Sverige	C/O Redia Ekonomi AB, Drottninggatan 32 111 51 Stockholm			30000	E/T	E/T				30000	
Svensk Gastroenterologisk Förening SGF	Göteborg	Sverige	Sahlgrenska Universitetssjukhuset Östra Kirurgi område 2 416 85 Göteborg			382500	E/T	E/T				382500	
SILF, Svenska Infektionsläkarföreningen	Örebro	Sverige	Infektionskliniken, Örebro Universitetssjukhus, Klostergatan 23 703 39 Örebro			74900	E/T	E/T				74900	
Torsby Sjukhus, medicinkliniken	Torsby	Sverige	Torsby Sjukhus Lasarettsvägen 685 34 Torsby			7514	E/T	E/T				7514	
Region Örebro län	Örebro	Sverige	Örebro Universitetssjukhus Region Örebro län Klostergatan 23 703 39 Örebro			46857	E/T	E/T				46857	
EMCG, European Microscopic Colitis Group	Linköping	Sverige	Linköping Universitetssjukhus, 581 85 Linköping	221355			E/T	E/T				221355	
Halfvämås Med AB	Örebro	Sverige	Tennisgatan 1, 702 25 Örebro				E/T	E/T	25000	139		25139	

HCO	Volvulus AB	Stockholm	Sverige	Karlbergsvägen 22 113 27 Stockholm			E/T	E/T	28'000		28'000	
	<i>ÖVRIGT, ej inräknat ovan - där information inte kan lämnas ut per HCO av legala skäl</i>											
	Totalt belopp hänförligt till värdeöverföringar till sådana mottagare - artikel 10											
						E/T	E/T	E/T	E/T	8'000	0	8'000
HCO	Antal mottagare											
						E/T	E/T	E/T	E/T	1	0	
	% av totala antalet mottagare enskilda HCOs - artikel 10											
					E/T	E/T	E/T	E/T	6%	0%		
Not: E/T = Ej tillämpligt												
F&U	TOTAL SUMMA											
	Värdeöverföringar för forskning & utveckling (se definition) (artikel 12 och artikel 1)											
											0	
Med hälso- och sjukvårdspersonal (HCP) avses läkare, tandläkare, farmaceut, sjuksköterska eller annan personal inom hälso- och sjukvården som har rätt att förskriva, köpa, tillhandahålla, rekommendera eller administrera läkemedel, inklusive anställd hos läkemedelsföretag vars huvudsakliga sysselsättning är inom hälso- och sjukvården. Övriga anställda hos läkemedelsföretag eller läkemedelsdistributör omfattas inte av begreppet hälso- och sjukvårdspersonal.												

Tillotts Pharma AB (“**Tillotts**”) Methodological note for HCP /HCO disclosure 2025 in Sweden (the “**Territory**”)

Data year: 2025

Year of publication: 2026

This methodological note explains the data disclosed by Tillotts for the 2025 reporting period and summarises the methodologies used to prepare the disclosure. Its purpose is to support understanding of the published Transfers of Value. Publication of this methodological note alongside the disclosure dataset is required under Chapter 2, Section 3, Article 4.3 of the LIF Ethical Rules for the Pharmaceutical Industry in Sweden (the “**Code**”) and forms part of the standardised EFPIA disclosure framework used for 2025 onward.

Contents

1. Definitions	2
1.1 Recipients	2
1.2 Kind of ToVs	2
2. Disclosure’s Scope	3
2.1 Products concerned.....	3
2.2 Company concerned	3
2.3 Excluded ToVs.....	3
2.4 ToVs date	3
2.5 Direct ToVs	3
2.6 Indirect ToVs	4
2.7 Non-monetary ToVs	4
2.8 ToVs in case of partial attendances or cancellation and refund.....	4
2.9 Cross-border activities	4
2.10 R&D.....	4
2.11 Voluntary disclosure.....	5
3. Specific considerations	5



3.1 Country unique identifier	5
3.2 Self-incorporated HCP	5
3.3 Multi-year agreements	5
3.4 Country specificities	5
3.5 Quality Checks	5
4. Data protection legal basis	6
4.1 Consent collection	6
4.2 Legitimate interests	6
5. Form of disclosure	6
5.1 Date of publication	6
5.2 Disclosure platform	6
5.3 Disclosure language	6
6. Disclosure financial data	6
6.1 Currency	6
6.2 VAT included or excluded	7
6.3 Calculation rules	7
7. Additional Information	7

1. Definitions

1.1 Recipients

Healthcare Professionals (HCPs): physicians, dentists, pharmacists, nurses, or other healthcare personnel who are authorized to prescribe, purchase, supply, recommend, or administer medicinal products.

Healthcare Organizations (HCOs): any legal entity that provides healthcare services, or conducts research or education in this field, or is an interest organization with a medical or scientific focus, excluding interest organizations as referred to in LER Chapter 3.

1.2 Kind of ToVs

Transfers of Value ("**ToV**") include

- Fees for service and consultancy (honoraria) and related expenses to HCPs
- Donations and grants to HCOs
- Contribution to costs related to events including sponsorships to HCOs
- Research and Development ToVs

Irrespective if they were directly effected by Tillotts or made via intermediaries or contracted third parties, and
Irrespective if they were made by Tillotts or by any of its affiliated companies for Recipients in the Territory.

2. Disclosure's Scope

2.1 Products concerned

Disclosures relate to prescription-only and over-the-counter medicines. One product includes medical device components; these are included in disclosure only insofar as they form part of the prescription medicine presentation. No stand alone medical device Transfers of Value are included.

2.2 Company concerned

Disclosures cover all ToVs made by Tillotts or any of its affiliated companies to Recipients based or residing in the Territory, with all cross-border activities consolidated into the dataset of the Territory, rather than reported separately. If the company name or structure changes in the future, such changes will be described in this section and cross referenced so that disclosures from previous years can still be identified and tracked by the public.

2.3 Excluded ToVs

The following ToVs are excluded from disclosure: ToVs related to

- Meals
- Information- and educational material and medical utility items
- Medical samples
- Purchases of ads

2.4 ToVs date

The disclosure covers Transfers of Value related to payments effected to Recipients during the 2025 calendar year.

2.5 Direct ToVs

Direct Transfers of Value include payments made directly to Recipients by Tillotts or one of its affiliated companies.

2.6 Indirect ToVs

Indirect Transfers of Value include payments made through third party intermediaries where the ultimate beneficiary is an identifiable HCP or HCO. These activities may involve support routed via event agencies or third party congress organisers, medical communications or educational partners delivering activities on behalf of Tillotts, or cross-border support provided by affiliated Tillotts entities to Recipients in the Territory. Indirect ToVs are disclosed once only, against the relevant individual or organisation.

2.7 Non-monetary ToVs

Non-monetary Transfers of Value include in kind contributions provided to identifiable HCPs or HCOs, such as travel, accommodation or registration fees paid directly by Tillotts. These transfers are disclosed at the value of the cost incurred.

2.8 ToVs in case of partial attendances or cancellation and refund

Transfers of Value are only reported for services and activities that have actually been performed. No disclosure is made for cancelled or non-attended services for which no payment has been made.

2.9 Cross-border activities

Transfers of Value provided to Recipients in the Territory by one of Tillotts affiliated companies outside the Territory are consolidated and disclosed within dataset of this Territory. Tillotts receives cross-border data from its affiliated companies and applies the same categorisation and verification checks used for all generated ToVs in the Territory. Cross-border transfers are disclosed once only, against the relevant Recipient in the Territory.

2.10 R&D

Research and Development Transfers of Value are disclosed in aggregated form and include Transfers of Value to Healthcare Professionals and Healthcare Organisations in Sweden related to:

- non-clinical studies (as defined in the OECD Principles of Good Laboratory Practice),
- clinical trials (as defined in Regulation (EU) No 536/2014),
- non-interventional studies that are prospective in nature and involve the collection of data from, or on behalf of, identifiable individuals or groups of Healthcare Professionals, and

– costs that are directly related and ancillary to these activities.

2.11 Voluntary disclosure

N/A

3. Specific considerations

3.1 Country unique identifier

Tillotts does not use or submit professional identifiers for Recipients in the course of the disclosure of ToVs.

3.2 Self-incorporated HCP

Where an HCP provides services through their own limited company or organisation, Tillotts report the Transfer of Value to the HCO.

3.3 Multi-year agreements

For multi-year agreements, Transfers of Value are allocated to the calendar year in which payment for the relevant services or activities were effected by Tillotts. Prepayments are recognised when the activity occurs, and any adjustments such as credit notes are applied to the year of the original transfer.

3.4 Country specificities

N/A

3.5 Quality Checks

Prior to submission, Tillotts undertakes internal quality checks to ensure that disclosures are accurate and complete. These checks include verifying data from internal systems such as finance and customer relationship management or Compliance management tools, cross-checking Transfers of Value against contracts and agreements, confirming correct categorisation, and reviewing currency, VAT and data-protection requirements. All checks are completed and reviewed internally before final approval and submission of the disclosure document.

4. Data protection legal basis

4.1 Consent collection

For contracted services (honoraria, consultancy, speaker engagements and related expenses), Tillotts uses Consent as the lawful basis for publishing individual-level data. Recipients are informed at the point of contracting through agreements and privacy notices. Partial consents are not accepted, in line with EFPIA guidance. Where consent is not given or is withdrawn, the related Transfers of Value are disclosed in aggregate. Withdrawals apply to future disclosures and may be submitted via dataprivacy@tillotts.com.

Transfers to HCOs do not require consent.

Cross-border processing is carried out under appropriate safeguards.

4.2 Legitimate interests

N/A

5. Form of disclosure

5.1 Date of publication

30/05/26

5.2 Disclosure platform

LIF's database for Transfer of Value: <https://www.lif.se/etik/vardeoverforing/>

5.3 Disclosure language

Swedish

6. Disclosure financial data

6.1 Currency

All disclosures are reported in Swedish krona (SEK). Where payments were originally made in another currency, Tillotts converts the amount into SEK using either the exchange rate applicable on the date of payment or the European Central Bank's average annual exchange rate for the relevant year, depending on the documentation available.

6.2 VAT included or excluded

Transfers of Value are reported excluding VAT. Salary, honoraria and expenses for fees paid out as salaries are reported as gross earnings, but no social security contributions are reported. For fees that are invoiced, the invoiced amount is paid and reported, excluding VAT.

6.3 Calculation rules

Transfers of Value are calculated using the actual cost incurred by Tillotts. In-kind or non-monetary Transfers of Value are disclosed at the value paid to secure the benefit provided. Where expenses include both business and non-business elements, only the business-related portion is disclosed. All values are rounded to two decimal places for publication

7. Additional Information

No additional methodological considerations apply.